# E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER) - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/e2cr2-periodic-benefit-risk-evaluation-report-pbrer/34160d8d-51b7-47bd-a753-e6ad93180322

> FDA guidance document: E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER). Issue date: July 18, 2016. Get complete insights and analysis.

---

## Details

- Title: E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER)
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2016-07-18
- Last Changed: 2022-12-29
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2012-D-0315">FDA-2012-D-0315</a>

## Related Documents

- [Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/q7-good-manufacturing-practice-guidance-for-active-pharmaceutical-ingredients-guidance-for-industry/4c33ca12-225d-4a88-aaa5-3f0f8357fdd9)
- [Contents of a Complete Submission for the Evaluation of Proprietary Names](https://www.globalkeysolutions.net/guidances/guidance-document/contents-of-a-complete-submission-for-the-evaluation-of-proprietary-names/8bbe789c-b7fd-4a76-9e78-6ea3344719df)
- [E2C(R2) Periodic Benefit-Risk Evaluation Report – Questions and Answers](https://www.globalkeysolutions.net/guidances/guidance-document/e2cr2-periodic-benefit-risk-evaluation-report-questions-and-answers/9735c0c5-468e-4e9b-a4c9-a7bad1eb9d94)